Leaflet ROGLUTEN 250mg tablets
Indicated for: Cushing syndrome; breast cancer
Route of administration: oral
Substance: aminoglutethimide (antineoplastic agent)
ATC: L02BG01 (Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Aminoglutethimide is a medication primarily used in the treatment of certain types of cancer, such as breast cancer and adrenal cancer, as well as in Cushing's syndrome. It works by inhibiting the synthesis of steroid hormones, including cortisol, estrogens, and androgens, through the blockade of the aromatase enzyme and other enzymes involved in steroid production.
Aminoglutethimide is administered orally, usually in tablet form, with the dosage adjusted based on the patient's response and the severity of the condition. The treatment requires careful monitoring, as it can affect adrenal gland function and lead to adrenal insufficiency.
Common side effects include drowsiness, dizziness, nausea, skin rashes, and muscle weakness. In rare cases, severe adverse reactions such as hepatotoxicity or bone marrow suppression may occur.
Patients taking aminoglutethimide should undergo regular monitoring for liver and adrenal function. Additionally, the medication may interact with other hormonal treatments, necessitating dose adjustments. Aminoglutethimide is an important therapeutic option for managing hormone-dependent conditions, but its use must be carefully supervised by a specialist physician.
General data about ROGLUTEN 250mg
- Substance: aminoglutethimide
- Date of latest medicines list: 01-04-2014
- Product code: W52201001
- Concentration: 250mg
- Pharmaceutical form: tablets
- Quantity: 40
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.